Repligen Corp (RGEN) is a publicly traded Healthcare sector company. As of May 20, 2026, RGEN trades at $108.55 with a market cap of $5.88B and a P/E ratio of 117.84. RGEN moved -1.01% today. Year to date, RGEN is -33.97%; over the trailing twelve months it is -14.00%. Its 52-week range spans $100.99 to $182.52. Analyst consensus is strong buy with an average price target of $176.23. Rallies surfaces RGEN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who is trading RGEN stock inside the company?
Recent RGEN insider activity includes Loeillot Olivier sold 3.83K, DAWES KAREN A sold 275, Loeillot Olivier sold 7.04K, Bylund James sold 2.19K, and Hunt Anthony sold 1.78K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
RGEN Key Metrics
Key financial metrics for RGEN
Metric
Value
Price
$108.55
Market Cap
$5.88B
P/E Ratio
117.84
EPS
$0.92
Dividend Yield
0.00%
52-Week High
$182.52
52-Week Low
$100.99
Volume
291.67K
Avg Volume
0
Revenue (TTM)
$763.34M
Net Income
$51.40M
Gross Margin
52.90%
Recent RGEN Insider Trades
Loeillot Olivier sold 3.83K (~$536.48K) on Apr 21, 2026.
DAWES KAREN A sold 275 (~$44.27K) on Dec 17, 2025.
Loeillot Olivier sold 7.04K (~$1.20M) on Nov 25, 2025.
Bylund James sold 2.19K (~$331.30K) on Nov 18, 2025.
Hunt Anthony sold 1.78K (~$269.40K) on Nov 13, 2025.
Recent RGEN insider activity includes Loeillot Olivier sold 3.83K, DAWES KAREN A sold 275, Loeillot Olivier sold 7.04K, Bylund James sold 2.19K, and Hunt Anthony sold 1.78K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for RGEN?
Yes. Rallies tracks RGEN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is RGEN research on Rallies investment advice?
No. Rallies provides research, data, and educational context for RGEN. It does not provide personalized investment advice.
